10 years ago

Enterprise Therapeutics Secures £1.6 Million Series A Funding for Respiratory Disease Therapeutics

  • Enterprise Therapeutics, a UK-based drug discovery company specializing in new therapeutics for respiratory diseases, has secured £1.6 million in Series A funding from Epidarex Capital

  • The company plans to use the funds for low molecular weight drug discovery and new target identification programs

  • Their lead indication is cystic fibrosis, the most common lethal genetic disease among Caucasians, with an estimated global patient population of 100,000.

      • ProblemHealthcare

      "Cystic fibrosis is a serious genetic disease that causes a buildup of thick mucus in the lungs, making it hard to breathe. The current treatments for cystic fibrosis are not always effective, and many people with cystic fibrosis die young. "

      Solution

      "Enterprise Therapeutics is developing new drugs that target the underlying mechanisms of mucus congestion, and could potentially lead to a cure for cystic fibrosis."

      Covered on